Esophageal cancer test kit ESOPHACAN™

oncologyfor precision medicineMSI

Gastrointestinal (GI) cancers are a group of cancers that affect the GI tract and accessory organs of the digestive system, such as colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer and gastrointestinal stromal tumor (GIST). Different treatment strategies are available for GI cancers depending on the cancer type and disease stage – including surgery, chemotherapy and radiation therapy, which may be employed alone or in-combination in a neoadjuvant or adjuvant set-up. With recent breakthroughs in uncovering the molecular basis of different GI cancers, targeted therapy and immunotherapy have proven effective in treating GI cancer patients with specific genetic biomarkers. Who Is It For  GI cancer patients seeking precision medicine   Patients with recurrent GI cancers  GI cancer patients resistant to targeted therapy   Sample Types Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others) Targets 58 key genes in esophageal cancer  Comprehensive testing of genetic alterations in RAS/RAF/MAPK and PI3K/AKT pathways, and other related protein kinase signaling cascades  Analyzes HER2 (ERBB2) gene mutations and copy number gain to better inform HER2 targeted therapy decisions Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions  Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers  Identifies potential drug resistance mechanisms  Assesses genetic predisposition to esophageal cancer